Order Article Reprints

Poh HM, Chiou YS, Chong QY, Chen R-M, Rangappa KS, Ma L, Zhu T, Kumar AP, Pandey V, Basappa, et al. Inhibition of TFF3 Enhances Sensitivity—and Overcomes Acquired Resistance—to Doxorubicin in Estrogen Receptor-Positive Mammary Carcinoma. Cancers. 2019; 11(10):1528. https://doi.org/10.3390/cancers11101528

Poh, Han Ming, Yi Shiou Chiou, Qing Yun Chong, Ru-Mei Chen, Kanchugarakoppal S. Rangappa, Lan Ma, Tao Zhu, Alan Prem Kumar, Vijay Pandey, Basappa, and et al. 2019. "Inhibition of TFF3 Enhances Sensitivity—and Overcomes Acquired Resistance—to Doxorubicin in Estrogen Receptor-Positive Mammary Carcinoma" Cancers 11, no. 10: 1528. https://doi.org/10.3390/cancers11101528

Poh, H. M., Chiou, Y. S., Chong, Q. Y., Chen, R.-M., Rangappa, K. S., Ma, L., Zhu, T., Kumar, A. P., Pandey, V., Basappa, Lee, S.-C., & Lobie, P. E. (2019). Inhibition of TFF3 Enhances Sensitivity—and Overcomes Acquired Resistance—to Doxorubicin in Estrogen Receptor-Positive Mammary Carcinoma. Cancers, 11(10), 1528. https://doi.org/10.3390/cancers11101528